Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) have been assigned an average rating of “Moderate Buy” from the eight analysts that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $48.38.

TARS has been the subject of a number of research reports. The Goldman Sachs Group lifted their price objective on Tarsus Pharmaceuticals from $19.00 to $30.00 and gave the stock a “neutral” rating in a research report on Thursday, February 29th. HC Wainwright increased their price objective on shares of Tarsus Pharmaceuticals from $50.00 to $57.00 and gave the company a “buy” rating in a report on Wednesday, February 28th. Barclays raised their price objective on shares of Tarsus Pharmaceuticals from $40.00 to $50.00 and gave the company an “overweight” rating in a research note on Wednesday, February 28th. Lifesci Capital restated an “outperform” rating on shares of Tarsus Pharmaceuticals in a report on Tuesday, December 26th. Finally, Jefferies Financial Group upped their price target on Tarsus Pharmaceuticals from $30.00 to $44.00 and gave the company a “buy” rating in a research note on Wednesday, March 6th.

Tarsus Pharmaceuticals Trading Down 0.5 %

TARS opened at $32.29 on Thursday. Tarsus Pharmaceuticals has a 1-year low of $12.57 and a 1-year high of $40.40. The stock has a market capitalization of $1.10 billion, a PE ratio of -6.96 and a beta of 1.05. The company has a current ratio of 6.93, a quick ratio of 6.85 and a debt-to-equity ratio of 0.15. The firm has a 50-day moving average price of $33.86 and a two-hundred day moving average price of $24.52.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings results on Tuesday, February 27th. The company reported ($1.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.06. The company had revenue of $13.08 million during the quarter, compared to analyst estimates of $4.63 million. During the same period in the prior year, the business earned ($0.49) EPS. As a group, equities analysts anticipate that Tarsus Pharmaceuticals will post -4.25 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Aziz Mottiwala sold 4,766 shares of the stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $30.60, for a total transaction of $145,839.60. Following the completion of the sale, the insider now directly owns 54,075 shares of the company’s stock, valued at approximately $1,654,695. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, insider Aziz Mottiwala sold 4,766 shares of the business’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $30.60, for a total value of $145,839.60. Following the sale, the insider now directly owns 54,075 shares of the company’s stock, valued at approximately $1,654,695. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel Bryan Wahl sold 4,436 shares of the stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $30.60, for a total value of $135,741.60. Following the transaction, the general counsel now owns 40,951 shares of the company’s stock, valued at approximately $1,253,100.60. The disclosure for this sale can be found here. Insiders have sold 24,496 shares of company stock worth $749,578 in the last 90 days. Corporate insiders own 11.54% of the company’s stock.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. RTW Investments LP grew its stake in shares of Tarsus Pharmaceuticals by 9.4% during the 4th quarter. RTW Investments LP now owns 3,152,341 shares of the company’s stock worth $63,835,000 after acquiring an additional 271,640 shares in the last quarter. Vanguard Group Inc. increased its stake in Tarsus Pharmaceuticals by 25.6% in the 3rd quarter. Vanguard Group Inc. now owns 1,551,802 shares of the company’s stock valued at $27,576,000 after buying an additional 316,128 shares during the last quarter. TFG Asset Management GP Ltd lifted its position in Tarsus Pharmaceuticals by 30.1% during the 4th quarter. TFG Asset Management GP Ltd now owns 800,000 shares of the company’s stock worth $16,200,000 after buying an additional 185,000 shares in the last quarter. Deerfield Management Company L.P. Series C acquired a new position in shares of Tarsus Pharmaceuticals during the 3rd quarter worth about $13,399,000. Finally, Artisan Partners Limited Partnership bought a new position in shares of Tarsus Pharmaceuticals in the 3rd quarter valued at about $7,093,000. Institutional investors and hedge funds own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.